Market Place
Sourcing Support
CASI Pharmaceuticals Reports Q3 2024 Business and Financial Results
15 Nov 2024 //
ACCESSWIRE
CASI Pharmaceuticals Receives CTA Approval for CID-103 in ITP
24 Oct 2024 //
ACCESSWIRE
CASI Pharmaceuticals to Join 2024 H.C. Wainwright Global Investment Conference
04 Sep 2024 //
PR NEWSWIRE
Casi Pharmaceuticals Announces Q2 2024 Business And Financial Results
16 Aug 2024 //
PR NEWSWIRE
Casi Pharmaceuticals Reports Development Relating to Disputes with Juvantas
19 Jul 2024 //
PR NEWSWIRE
Casi Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
08 Jul 2024 //
PR NEWSWIRE
CASI Pharmaceuticals Announces $15M Private Placement Financing
26 Jun 2024 //
PR NEWSWIRE
CASI Pharmaceuticals To Submit IND For CID-103, Receives Acquisition Proposal
26 Jun 2024 //
PR NEWSWIRE
CASI Pharmaceuticals Receives FDA Clearance On The IND App For CID-103 In ITP
15 May 2024 //
PR NEWSWIRE
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
14 May 2024 //
PR NEWSWIRE
Casi Pharmaceuticals Reports Development Relating to Its Disputes with Juventas
08 Apr 2024 //
PR NEWSWIRE
Casi Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
28 Mar 2024 //
PR NEWSWIRE
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206
05 Mar 2024 //
PR NEWSWIRE
Casi Pharmaceuticals Announces First Dosing Of Folotyn® In China
16 Feb 2024 //
PR NEWSWIRE
Casi Pharmaceuticals Announces Third Quarter 2023 Business And Financial Updates
14 Nov 2023 //
PR NEWSWIRE
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
08 Nov 2023 //
PR NEWSWIRE
Casi Pharmaceuticals Announces Second Quarter 2023 Business & Financial Updates
11 Aug 2023 //
PR NEWSWIRE
CASI Pharm Acquires Global Intellectual Property Rights to Cleave`s CB-533
20 Jul 2023 //
PR NEWSWIRE
BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave’ assets
20 Jul 2023 //
ENDPTS
Casi Pharmaceuticals Announces First Quarter 2023 Financial Results
17 May 2023 //
PR NEWSWIRE
CASI Pharmaceuticals ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FYR
26 Apr 2023 //
PR NEWSWIRE
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
26 Apr 2023 //
PR NEWSWIRE
Casi Pharmaceuticals Completes Redomiciliation Merger
21 Mar 2023 //
PR NEWSWIRE
CASI AND CLEAVE THERAPEUTICS ANNOUNCE TRIAL APPLICATION APPROVAL FOR CB-5339
06 Jan 2023 //
PR NEWSWIRE
Casi Pharmaceuticals` Partner Juventas Announces NDA For Cnct19 Accepted By NMPA
15 Dec 2022 //
PRNEWSWIRE
CASI & Bioinvent Announce Dosing of First Patient In Bi-1206 Phase 1 Trial
07 Sep 2022 //
PRNEWSWIRE
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS
12 Aug 2022 //
PRNEWSWIRE
Casi Pharmaceuticals To Report Second Quarter 2022 Financial Results
05 Aug 2022 //
PRNEWSWIRE
Precision Autoimmune Tx Has Completed First-Round Financing Of $21M
08 Jul 2022 //
PRNEWSWIRE
Casi Pharmaceuticals Announces Reverse Stock Split
26 May 2022 //
PRNEWSWIRE
CASI PHARMA ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS
24 May 2022 //
PRNEWSWIRE
Casi Pharmaceuticals To Report First Quarter 2022 Financial Results
02 May 2022 //
PRNEWSWIRE
CASI PHARMA STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT
01 Apr 2022 //
PRNEWSWIRE
Casi Pharma To Report Q4 And Year End 2021 Financial Results
23 Mar 2022 //
PRNEWSWIRE
Casi Pharma RenewsExclusive Distribution Agreement For Evomela
04 Mar 2022 //
PRNEWSWIRE
Casi Pharmaceuticals Announces Preliminary Q4 And Full-Year 2021 Revenues
16 Feb 2022 //
PRNEWSWIRE
FDA Grants ODD to BioInvent`s BI-1206 for follicular lymphoma.
20 Jan 2022 //
PRNEWSWIRE
Casi Pharma announces CNCT19 (CD19 CAR-T) granted ODD by The U.S. FDA
18 Jan 2022 //
PRNEWSWIRE
CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results
12 Nov 2021 //
PRNEWSWIRE
CASI Pharma Announces Partner Juventas Completion Of Series C Of $63 M
25 Oct 2021 //
PRNEWSWIRE
Juventas Cell Therapy closes a $63M funding round
25 Oct 2021 //
FIERCEBIOTECH
CASI Pharma To Participate In Oppenheimer Fall Healthcare & MedTech Summit
20 Sep 2021 //
PRNEWSWIRE
CASI Pharma Announces Dosing Of 1st Patient Of CID-103 In Phase 1 Clinical Trial
10 Jun 2021 //
PRNEWSWIRE
CASI Pharmaceuticals, To Participate In Jefferies Virtual Healthcare Conference
27 May 2021 //
PRNEWSWIRE
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
23 Mar 2021 //
PRNEWSWIRE
CASI Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy
22 Dec 2020 //
PRNEWSWIRE
CASI Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy
22 Dec 2020 //
PRNEWSWIRE
BioInvent licenses anti-Fc?RllB antibody BI-1206 to CASI Pharmaceuticals
26 Oct 2020 //
PRNEWSWIRE
CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB
02 Oct 2020 //
PRNEWSWIRE
CASI Announces Restructuring of Partnership with Juventas Cell Therapy Ltd
29 Sep 2020 //
PRNEWSWIRE
CASI Pharma Announces Submission Of Clinical Trial Application (IND)
08 Jun 2020 //
PRNEWSWIRE
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
02 Jun 2020 //
PRNEWSWIRE
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19
03 Dec 2019 //
BIO SPACE
CASI`S Enters Exclusive China Distribution License Agreement For Octreotide
07 Nov 2019 //
PR NEWSWIRE
CASI Pharma Announces Launch of EVOMELA® (melphalan injection) in China
12 Aug 2019 //
PR NEWSWIRE
CASI Pharmaceuticals Acquires Rights To Commercialize anti-CD19 T-cell Therapy
17 Jun 2019 //
PRESS RELEASE
CASI Enters Exclusive China Distribution License Agreement For LAI
05 Jun 2019 //
PRNEWSWIRE
CASI Announces Exclusive Distribution Partner For (EVOMELA®) In China
13 Mar 2019 //
BIOSPACE
CASI Pharma Announces China National Medical Products Administration (NMPA)
19 Feb 2019 //
PR NEWSWIRE
